{"id":68399,"date":"2026-06-17T15:26:57","date_gmt":"2026-06-17T07:26:57","guid":{"rendered":"https:\/\/flcube.com\/?p=68399"},"modified":"2026-06-17T15:26:58","modified_gmt":"2026-06-17T07:26:58","slug":"nmpa-releases-106th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation-including-beone-medicines-brukinsa-zanubrutinib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68399","title":{"rendered":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#8217; Brukinsa (zanubrutinib)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>National Medical Products Administration (NMPA)<\/strong> announced the <strong>106th batch<\/strong> of reference drugs designated for <strong>Generic Quality Consistency Evaluation (GQCE)<\/strong> work, comprising <strong>38 drug specifications<\/strong> in total. The list includes <strong>Brukinsa (zanubrutinib)<\/strong>, a <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong> developed by <strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>), formerly known as BeiGene.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-overview\" class=\"wp-block-heading\">Regulatory Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Authority<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Batch Number<\/strong><\/td><td>106th batch of GQCE reference drugs<\/td><\/tr><tr><td><strong>Total Specifications<\/strong><\/td><td>38 drug specifications<\/td><\/tr><tr><td><strong>Featured Product<\/strong><\/td><td>Brukinsa (zanubrutinib)<\/td><\/tr><tr><td><strong>Innovator Company<\/strong><\/td><td>BeOne Medicines Ltd. (formerly BeiGene)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/td><\/tr><tr><td><strong>Stock Listings<\/strong><\/td><td>NASDAQ: ONC, HKG: 6160, SHA: 688235<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-market-significance\" class=\"wp-block-heading\">Product Profile &amp; Market Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Zanubrutinib \u2013 second-generation BTK inhibitor<\/li>\n\n\n\n<li><strong>Brand Name:<\/strong> Brukinsa \u2013 globally recognized oncology therapeutic<\/li>\n\n\n\n<li><strong>Therapeutic Indications:<\/strong> Approved for multiple B-cell malignancies including mantle cell lymphoma (MCL), Waldenstr\u00f6m&#8217;s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL)<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> Designed to maximize BTK occupancy while minimizing off-target effects compared to first-generation inhibitors<\/li>\n\n\n\n<li><strong>Global Presence:<\/strong> Approved in multiple major markets including China, United States, European Union, and other jurisdictions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-gqce-program-context-amp-strategic-implications\" class=\"wp-block-heading\">GQCE Program Context &amp; Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-generic-quality-consistency-evaluation-framework\" class=\"wp-block-heading\">Generic Quality Consistency Evaluation Framework<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Program Objective:<\/strong> Ensure generic drugs demonstrate equivalent quality, safety, and efficacy to their reference listed counterparts<\/li>\n\n\n\n<li><strong>Reference Drug Status:<\/strong> Inclusion in NMPA&#8217;s reference drug list establishes Brukinsa as the benchmark for future generic zanubrutinib applications<\/li>\n\n\n\n<li><strong>Market Exclusivity Impact:<\/strong> Reference drug designation may influence market dynamics for potential generic entrants<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Generic manufacturers must conduct bioequivalence studies against Brukinsa to gain marketing approval<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-impact-analysis\" class=\"wp-block-heading\">Market Impact Analysis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Market Value:<\/strong> BTK inhibitors represent a high-value segment in hematologic oncology with significant commercial potential<\/li>\n\n\n\n<li><strong>BeOne Medicines Position:<\/strong> Reference drug status reinforces BeOne&#8217;s leadership position in China&#8217;s innovative oncology landscape<\/li>\n\n\n\n<li><strong>Generic Competition Timeline:<\/strong> GQCE inclusion signals potential pathway for future generic competition, though patent protections may limit near-term impact<\/li>\n\n\n\n<li><strong>Healthcare Accessibility:<\/strong> Long-term goal supports improved patient access to essential oncology treatments through cost-effective generic alternatives<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The inclusion of Brukinsa in the NMPA&#8217;s 106th GQCE reference drug batch represents both recognition of BeOne Medicines&#8217; innovative achievement and preparation for eventual generic competition in China&#8217;s evolving pharmaceutical market. While immediate generic entry is unlikely due to patent protections, the designation establishes the regulatory framework for future bioequivalence requirements. This move aligns with China&#8217;s broader strategy to balance innovation incentives with long-term healthcare cost containment through quality-assured generic alternatives.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory implications and market dynamics. Actual outcomes may differ based on patent expiration timelines, generic development progress, and evolving regulatory policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[2092,103,847,3046,848],"class_list":["post-68399","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-beone-medicines","tag-gqce-testing","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#039; Brukinsa (zanubrutinib) - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for Generic Quality Consistency Evaluation (GQCE) work, comprising 38 drug specifications in total. The list includes Brukinsa (zanubrutinib), a Bruton&#039;s tyrosine kinase (BTK) inhibitor developed by BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68399\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#039; Brukinsa (zanubrutinib)\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68399\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T07:26:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#8217; Brukinsa (zanubrutinib)\",\"datePublished\":\"2026-06-17T07:26:57+00:00\",\"dateModified\":\"2026-06-17T07:26:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeOne Medicines\",\"GQCE testing\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68399#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68399\",\"name\":\"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines' Brukinsa (zanubrutinib) - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T07:26:57+00:00\",\"dateModified\":\"2026-06-17T07:26:58+00:00\",\"description\":\"The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for Generic Quality Consistency Evaluation (GQCE) work, comprising 38 drug specifications in total. The list includes Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor developed by BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68399\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68399#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#8217; Brukinsa (zanubrutinib)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines' Brukinsa (zanubrutinib) - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for Generic Quality Consistency Evaluation (GQCE) work, comprising 38 drug specifications in total. The list includes Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor developed by BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68399","og_locale":"en_US","og_type":"article","og_title":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines' Brukinsa (zanubrutinib)","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=68399","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T07:26:57+00:00","article_modified_time":"2026-06-17T07:26:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68399#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68399"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#8217; Brukinsa (zanubrutinib)","datePublished":"2026-06-17T07:26:57+00:00","dateModified":"2026-06-17T07:26:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68399"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeOne Medicines","GQCE testing","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68399#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68399","url":"https:\/\/flcube.com\/?p=68399","name":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines' Brukinsa (zanubrutinib) - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T07:26:57+00:00","dateModified":"2026-06-17T07:26:58+00:00","description":"The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for Generic Quality Consistency Evaluation (GQCE) work, comprising 38 drug specifications in total. The list includes Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor developed by BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68399#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68399"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68399#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines&#8217; Brukinsa (zanubrutinib)"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68399"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68399\/revisions"}],"predecessor-version":[{"id":68400,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68399\/revisions\/68400"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}